TRIPS to Doha to Bilateral FTAs
From PHM Oz
(Difference between revisions)
| Line 1: | Line 1: | ||
<center>''This page is under construction, please be patient as we develop it further''</center> | <center>''This page is under construction, please be patient as we develop it further''</center> | ||
| + | Story of policy development internationally on IP protection. | ||
| + | |||
| + | patents, prices and access | ||
| + | |||
| + | impact of TRIPS | ||
| + | |||
| + | bilateral free trade and TRIPS plus (data exclusivity, evergreening, patent extensions (for unreasonable delays)) | ||
| + | |||
| + | reform pressures and options: differential pricing, parallel importation, compulsory licensing | ||
| + | |||
| + | Doha statement; | ||
| + | |||
| + | compulsory licensing farce; | ||
[[Intellectual Property and Pharmaceuticals|Back to IP home]] | [[Intellectual Property and Pharmaceuticals|Back to IP home]] | ||
Revision as of 04:03, 16 June 2007
Story of policy development internationally on IP protection.
patents, prices and access
impact of TRIPS
bilateral free trade and TRIPS plus (data exclusivity, evergreening, patent extensions (for unreasonable delays))
reform pressures and options: differential pricing, parallel importation, compulsory licensing
Doha statement;
compulsory licensing farce;
